Kineta, Inc. (KA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and technology synergies build on TuHURA's therapeutic focus on overcoming primary and acquired resistance to cancer immunotherapy Proposed Transaction expected to close in Q1 2025 TAMPA, FL AND SEATTLE, WA / ACCESSWIRE / December 12, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta, Inc. (OTC PINK:KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today announced that they have entered into a definitive merger agreement in which TuHURA would acquire Kineta, including the rights to Kineta's novel KVA12123 antibody, for a combination of cash and shares of TuHURA common stock via a merger transaction (the "Proposed Transaction"). "We are pleased to have entered into this definitive agreement with Kineta, which represents the culmination of the Exclusivity and Right of First Offer Agreement that TuHURA and Kineta entered into in July 2024.
Kineta, Inc. (KA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kineta, Inc. ever had a stock split?
Kineta, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Craig W. Philips CEO | NASDAQ (CM) Exchange | 49461C102 CUSIP |
| US Country | 11 Employees | - Last Dividend | 19 Dec 2022 Last Split | 11 Feb 2016 IPO Date |
Overview
Kineta, Inc. is a pioneering clinical-stage biotechnology entity focusing on the innovation of transformative immunotherapies designed to improve the lives of patients worldwide. With its inception in 2007 and headquartered in Seattle, Washington, the company stands at the forefront of addressing the existing limitations in cancer therapy through its commitment to developing unique immunotherapeutic solutions. Leveraging strategic collaborations and license agreements with industry leaders like MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc., Kineta, Inc. endeavors to advance its mission of bringing novel treatments from bench to bedside.
Products and Services
-
KVA12123
Kineta, Inc.’s flagship product, KVA12123, represents a pioneering VISTA blocking immunotherapy, engineered as a monoclonal antibody (mAb) for twice-weekly infusion. Currently undergoing a Phase 1/2 clinical trial, KVA12123 is being tested both as a standalone therapy and in combination with pembrolizumab. Targeting patients with advanced solid tumors, including non-small cell lung, ovarian, head and neck, renal cell, and colorectal cancers, KVA12123 aims to redefine the standards of cancer immunotherapy through its innovative approach to modulating the immune response.
-
Anti-CD27 Agonist mAb Immunotherapy
In the realm of preclinical development lies Kineta’s anti-CD27 agonist mAb immunotherapy, a testament to the company’s commitment to expanding its portfolio of cancer treatments. Designed to potentiate the immune system's fight against tumors, this immunotherapy is being developed for a range of advanced solid tumors, with a focus on renal cell carcinoma, ovarian, and colorectal cancers. This novel agent underscores Kineta's dedication to leveraging immune activation pathways for cancer treatment.
